ARTL
Income statement / Annual
Last year (2024), Artelo Biosciences, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Artelo Biosciences, Inc.'s net income was -$9.83 M.
See Artelo Biosciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
08/31/2021 |
08/31/2020 |
08/31/2019 |
08/31/2018 |
08/31/2017 |
08/31/2016 |
08/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$5.99 M
|
$5.70 M
|
$4.32 M
|
$2.84 M
|
$1.92 M
|
$1.09 M
|
$1.25 M
|
$0.00
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$4.12 M
|
$4.23 M
|
$5.96 M
|
$4.60 M
|
$2.77 M
|
$2.12 M
|
$1.09 M
|
$232.79 K
|
$29.69 K
|
$15.24 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$4.12 M
|
$4.23 M
|
$5.96 M
|
$4.60 M
|
$2.77 M
|
$2.12 M
|
$1.09 M
|
$232.79 K
|
$29.69 K
|
$15.24 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.41 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$10.11 M
|
$9.93 M
|
$10.29 M
|
$7.44 M
|
$4.69 M
|
$3.21 M
|
$2.34 M
|
$232.79 K
|
$29.69 K
|
$15.24 K
|
| Cost And Expenses |
$10.11 M
|
$9.93 M
|
$10.29 M
|
$7.44 M
|
$4.69 M
|
$3.21 M
|
$2.34 M
|
$232.79 K
|
$29.69 K
|
$15.24 K
|
| Interest Income |
$0.00
|
$0.00
|
$2.00 K
|
$2.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$5.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.10 K
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$500.00
|
$510.00
|
$282.00
|
$600.00
|
$22.82 K
|
$0.00
|
| EBITDA |
-$10.11 M |
-$9.93 M |
-$10.08 M |
-$7.44 M |
-$4.72 M |
-$4.22 M |
-$2.34 M |
-$232.79 K |
-$29.69 K |
-$15.24 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$282.00 K
|
$641.00 K
|
$204.00 K
|
$4.00 K
|
$30.00 K
|
$1.04 M
|
$0.00
|
-$2.10 K
|
$0.00
|
$0.00
|
| Income Before Tax |
-$9.83 M
|
-$9.29 M
|
-$10.08 M
|
-$7.44 M
|
-$4.66 M
|
-$2.17 M
|
-$2.34 M
|
-$234.89 K
|
-$29.69 K
|
-$15.24 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$2.04 M
|
$8.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$9.83 M
|
-$9.29 M
|
-$10.08 M
|
-$7.44 M
|
-$4.65 M
|
-$2.17 M
|
-$2.34 M
|
-$234.89 K
|
-$29.69 K
|
-$15.24 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-3.05 |
-3.14 |
-3.49 |
-5.97 |
-18.83 |
-15 |
-27.52 |
-3.23 |
-0.47 |
-0.24 |
| EPS Diluted |
-3.05 |
-3.14 |
-3.49 |
-5.97 |
-18.83 |
-15 |
-27.52 |
-3.23 |
-0.47 |
-0.24 |
| Weighted Average Shares Out |
$3.22 M
|
$2.96 M
|
$472.00 K
|
$207.50 K
|
$41.17 K
|
$24.00 K
|
$14.00 K
|
$12.00 K
|
$10.50 K
|
$10.61 K
|
| Weighted Average Shares Out Diluted |
$3.22 M
|
$2.96 M
|
$472.17 K
|
$207.50 K
|
$41.20 K
|
$24.14 K
|
$14.19 K
|
$12.13 K
|
$10.61 K
|
$10.61 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
